BRIM BIOTECHNOLOGY, INC.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 24
- Market Cap
- -
- Website
- http://www.brimbiotech.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
3 Phases
Phase 2:3
Phase 3:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Not Applicable
1 (20.0%)Phase 3
1 (20.0%)A Phase 2 Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Not Applicable
Not yet recruiting
- Conditions
- Dry Eye Disease (DED)Keratoconjunctivitis Sicca
- Interventions
- Drug: Vehicle Ophthalmic SolutionDrug: BRM421 Ophthalmic Solution, 0.03%Drug: BRM421 Ophthalmic Solution, 0.06%
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- BRIM Biotechnology Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT07078955
- Locations
- 🇨🇳
New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Phase 2
Recruiting
- Conditions
- Neurotrophic Keratitis
- Interventions
- Drug: BRM424 Ophthalmic Solution - Dose1Drug: BRM424 Ophthalmic Solution - Dose2
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BRIM Biotechnology Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05927428
- Locations
- 🇺🇸
Wilmington Eye, Leland, North Carolina, United States
Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
Phase 3
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: BRM421 Ophthalmic SolutionDrug: Vehicle
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- BRIM Biotechnology Inc.
- Target Recruit Count
- 740
- Registration Number
- NCT05695781
- Locations
- 🇺🇸
Andover Eye Associates, Warwick, Rhode Island, United States
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- BRIM Biotechnology Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT04343287
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸Midwest Cornea Associates, LLC, Indianapolis, Indiana, United States
🇺🇸Andover Eye Associates, Andover, Massachusetts, United States
Safety and Efficacy of BRM421 for Dry Eye Syndrome
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- BRIM Biotechnology Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT03066219
- Locations
- 🇺🇸
Central Maine Eye Care, Lewiston, Maine, United States
🇺🇸Andover Eye Associates, Andover, Massachusetts, United States
News
No news found